DNA repair dysregulation from cancer driver to therapeutic target

Curtin, Nicola J.·2012·Nature Reviews Cancer
DOI 10.1038/nrc3399

Cites (202)

Items 201–202 of 202

  1. Final results from a phase I study of oral TRC102 (methoxyamine HCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexed in patients with refractory cancer.
    Glen J. Weiss, Michael Solomon Gordon, Lee S. Rosen · 2010 · Journal of Clinical Oncology
  2. The novel poly(ADP-ribose) polymerase (PARP) -1 Inhibitor, BSI-401, has antitumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer
    Davide Melisi, Valeria Ossovskaya, Barry M. Sherman · 2007 · Molecular Cancer Therapeutics